Other languages IPH Limited

Equities

Delayed Australian S.E. Other stock markets 04:32:41 03/05/2024 BST			5-day change	1st Jan Change
6.14 ^AUD	+0.16%		-1.13%	-4.21%

02-29	IPH Limited Announces Executive Changes	CI
02-28	IPH Managing Director Pares Shareholding in Firm	MT

IPH Limited Announces Executive Changes	02-29
IPH Managing Director Pares Shareholding in Firm	02-28
IPH Reports H1 FY24 Revenue Up 22%, EPS of AU$0.0879	02-21
IPH Ltd. Reports H1 FY24 Revenue Up 21% to AU$274.4 Million; Underlying Diluted EPS of AU$0.212	02-21
IPH Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-21
US FDA Ends Partial Clinical Hold on Innate Pharma's Investigational Cancer Drug	01-04
Sanofi Licenses Natural Killer Cell Engager Program from Innate Pharma	12-19
IPH Completes ROBIC Business Acquisition	12-18
IPH Limited completed the acquisition of ROBIC L.L.P.	12-14
IPH Announces Third Canadian Acquisition with AU$124 Million Deal	11-22
IPH Managing Director and CEO Sells Company Shares	11-22
IPH Limited Approves Election of Director, David Wiadrowski	11-15
IPH Limited Seeks Acquisitions	11-14
IPH Completes AU$75 Million Acquisition of Canadian IP Services Firm	02/10/23
Australia Inc roiled by string of cyber attacks since late 2022	29/09/23
IPH's Net Profit Jumps 23% in Fiscal Year 2023; Shares Rally 10%	17/08/23
IPH Limited Seeks Acquisitions	17/08/23
IPH Limited Reports Earnings Results for the Full Year Ended June 30, 2023	16/08/23
IPH Limited Declares Final Dividend for the Fiscal Year 2023, Payable on 15 September 2023	16/08/23
Innate Pharma Starts Early-stage Study of Blood Cancer Drug	11/07/23

No results for this search